

Javier Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4692957/publications.pdf>

Version: 2024-02-01

84
papers

6,563
citations

81743

39
h-index

64668

79
g-index

87
all docs

87
docs citations

87
times ranked

6042
citing authors

#	ARTICLE	IF	CITATIONS
1	The Intestinal Gas Questionnaire (IGQ): Psychometric validation of a new instrument for measuring gas-related symptoms and their impact on daily life among general population and irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14202.	1.6	5
2	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 147-157.	0.2	39
3	Editorial: Human Intestinal Permeability, Mucosal Inflammation and Diet. <i>Frontiers in Nutrition</i> , 2022, 9, 894869.	1.6	1
4	Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction. <i>Cells</i> , 2022, 11, 1644.	1.8	7
5	Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations. <i>Cells</i> , 2022, 11, 2046.	1.8	4
6	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	0.6	913
7	Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 325-331.	1.4	5
8	The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults. <i>Advances in Therapy</i> , 2021, 38, 2054-2076.	1.3	8
9	<i>Blastocystis</i> sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?. <i>Biology</i> , 2021, 10, 340.	1.3	4
10	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8047-8061.	1.6	5
11	Present and Future Therapeutic Approaches to Barrier Dysfunction. <i>Frontiers in Nutrition</i> , 2021, 8, 718093.	1.6	21
12	A Fermented Milk Product Containing <i>B. lactis</i> CNCM I-2494 Improves the Tolerance of a Plant-Based Diet in Patients with Disorders of Gut-Brain Interactions. <i>Nutrients</i> , 2021, 13, 4542.	1.7	1
13	A novel distinctive form of identification for differential diagnosis of irritable bowel syndrome, inflammatory bowel disease, and healthy controls. <i>GastroHep</i> , 2020, 2, 193-204.	0.3	3
14	Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2020, 10, 20706.	1.6	21
15	Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2020, 115, 2047-2059.	0.2	16
16	Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial. <i>United European Gastroenterology Journal</i> , 2019, 7, 1093-1101.	1.6	33
17	Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G701-G719.	1.6	7
18	Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis. <i>Cells</i> , 2019, 8, 135.	1.8	115

#	ARTICLE	IF	CITATIONS
19	Anemia microcítica secundaria a úlcera anastomótica ileocecal. Gastroenterología Y Hepatología, 2019, 42, 111-112.	0.2	0
20	A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Advances in Therapy, 2018, 35, 289-310.	1.3	152
21	Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction. Scientific Reports, 2018, 8, 2255.	1.6	18
22	Postinfectious IBS: Defining its clinical features and prognosis using an internet-based survey. United European Gastroenterology Journal, 2018, 6, 1245-1253.	1.6	40
23	Consensus document on exclusion diets in irritable bowel syndrome (IBS). Revista Espanola De Enfermedades Digestivas, 2018, 110, 806-824.	0.1	6
24	Consensus document on exclusion diets in irritable bowel syndrome (IBS). Nutricion Hospitalaria, 2018, 35, 1450.	0.2	2
25	Effect of prucalopride on intestinal gas tolerance in patients with functional bowel disorders and constipation. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1457-1462.	1.4	12
26	Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. Advances in Therapy, 2017, 34, 587-598.	1.3	23
27	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. Gut, 2017, 66, 1537.1-1538.	6.1	105
28	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2017, 45, 909-922.	1.9	81
29	Effect of Chicory-derived Inulin on Abdominal Sensations and Bowel Motor Function. Journal of Clinical Gastroenterology, 2017, 51, 619-625.	1.1	25
30	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Scientific Reports, 2017, 7, 14680.	1.6	46
31	Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterology Journal, 2017, 5, 887-897.	1.6	40
32	Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 53-63.	1.4	47
33	Cognitive and hedonic responses to meal ingestion correlate with changes in circulating metabolites. Neurogastroenterology and Motility, 2016, 28, 1806-1814.	1.6	27
34	Epidemiological and clinical profile of adult patients with Blastocystis sp. infection in Barcelona, Spain. Parasites and Vectors, 2016, 9, 548.	1.0	26
35	The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology, 2016, 150, 1305-1318.e8.	0.6	243
36	Effect of selective CCK ₁ receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 288-293.	1.4	8

#	ARTICLE	IF	CITATIONS
37	The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016, 28, 463-486.	1.6	62
38	Lessons learned resolving the enigma of genetic factors in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 77-87.	8.2	76
39	The role of mast cells in functional GI disorders. <i>Gut</i> , 2016, 65, 155-168.	6.1	251
40	Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2015, 5, 12693.	1.6	248
41	Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 033-050.	0.8	84
42	144 Jejunal Mucosal Eosinophils Show Higher Corticotropin-Releasing Hormone Content in Association With Clinical Manifestations in Diarrhea-Prone Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015, 148, S-38.	0.6	2
43	Su1386 Clinical Benefit and Intestinal Mucosal Transcriptome Modulation After Long-Term Mast Cell Stabilization With Oral Disodium Cromoglycate in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Patients. <i>Gastroenterology</i> , 2015, 148, S-494.	0.6	4
44	Classification of functional bowel disorders by objective physiological criteria based on endoluminal image analysis. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G413-G419.	1.6	31
45	Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. <i>Gut</i> , 2015, 64, 1379-1388.	6.1	94
46	Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. <i>Gut</i> , 2014, 63, 401-408.	6.1	104
47	Intestinal Barrier Function and the Brain-Gut Axis. <i>Advances in Experimental Medicine and Biology</i> , 2014, 817, 73-113.	0.8	43
48	Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms. <i>Neurogastroenterology and Motility</i> , 2014, 26, 779-785.	1.6	24
49	Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. <i>Gut</i> , 2014, 63, 262-271.	6.1	322
50	Response to Rodrigo et al.. <i>American Journal of Gastroenterology</i> , 2014, 109, 1291-1292.	0.2	1
51	Vitamin E and Vitamin E Acetate Absorption from Self-assembly Systems under Pancreas Insufficiency Conditions. <i>Chimia</i> , 2014, 68, 129.	0.3	9
52	Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. <i>Gut</i> , 2013, 62, 1160-1168.	6.1	229
53	Double-balloon jejunal perfusion to compare absorption of vitamin E and vitamin E acetate in healthy volunteers under maldigestion conditions. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 202-206.	1.3	20
54	The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations. <i>American Journal of Gastroenterology</i> , 2012, 107, 736-746.	0.2	169

#	ARTICLE	IF	CITATIONS
55	Cellular and Molecular Basis of Intestinal Barrier Dysfunction in the Irritable Bowel Syndrome. <i>Gut and Liver</i> , 2012, 6, 305-315.	1.4	95
56	Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction. <i>Psychoneuroendocrinology</i> , 2012, 37, 65-77.	1.3	62
57	Functional gut disorders or disordered gut function? Small bowel dysmotility evidenced by an original technique. <i>Neurogastroenterology and Motility</i> , 2012, 24, 223.	1.6	34
58	Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability. <i>Neurogastroenterology and Motility</i> , 2012, 24, 740.	1.6	55
59	Eosinophils Express Muscarinic Receptors and Corticotropin-Releasing Factor to Disrupt the Mucosal Barrier in Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, 1597-1607.	0.6	68
60	Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2010, 22, 401-e92.	1.6	42
61	Role of microRNA in IBS with increased gut permeability. <i>Gut</i> , 2010, 59, 710-712.	6.1	12
62	Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. <i>Gut</i> , 2010, 59, 12-20.	6.1	191
63	Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1166-1175.	2.0	88
64	Editorial: A Closer Look at Mucosal Inflammation in Irritable Bowel Syndrome: Sex- and Gender-Related Disparities—Quantity, Quality, or Both?. <i>American Journal of Gastroenterology</i> , 2009, 104, 401-403.	0.2	5
65	Impaired intestinal molecular tightness in the mucosa of irritable bowel syndrome: what are the mediators?. <i>Gut</i> , 2009, 58, 161-162.	6.1	4
66	Metabotyping of Biofluids Reveals Stress-Based Differences in Gut Permeability in Healthy Individuals. <i>Journal of Proteome Research</i> , 2009, 8, 4799-4809.	1.8	33
67	Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. <i>Psychoneuroendocrinology</i> , 2008, 33, 1248-1256.	1.3	61
68	Maladaptive Intestinal Epithelial Responses to Life Stress May Predispose Healthy Women to Gut Mucosal Inflammation. <i>Gastroenterology</i> , 2008, 135, 163-172.e1.	0.6	112
69	Unstable Composition of the Fecal Microbiota in Ulcerative Colitis During Clinical Remission. <i>American Journal of Gastroenterology</i> , 2008, 103, 643-648.	0.2	175
70	Neuropharmacology of Stress-Induced Mucosal Inflammation: Implications for Inflammatory Bowel Disease and Irritable Bowel Syndrome. <i>Current Molecular Medicine</i> , 2008, 8, 258-273.	0.6	28
71	Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. <i>Gut</i> , 2007, 56, 203-209.	6.1	330
72	Targeting mast cells in the treatment of functional gastrointestinal disorders. <i>Current Opinion in Pharmacology</i> , 2006, 6, 541-546.	1.7	50

#	ARTICLE	IF	CITATIONS
73	Anisakis Simplex-Induced Small Bowel Obstruction After Fish Ingestion: Preliminary Evidence for Response to Parenteral Corticosteroids. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 667-671.	2.4	23
74	Pathogenesis of irritable bowel syndrome: The mast cell connection. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 129-140.	0.6	74
75	Prevalence of Functional Gastrointestinal Disorders in Women Who Report Domestic Violence to the Police. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 436-441.	2.4	35
76	Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH. <i>Digestive Diseases and Sciences</i> , 2002, 47, 208-215.	1.1	165
77	Adaptation of stress-induced mucosal pathophysiology in rat colon involves opioid pathways. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, G124-G128.	1.6	26
78	Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. <i>Gut</i> , 2001, 48, 630-636.	6.1	256
79	Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G847-G854.	1.6	153
80	Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G391-G399.	1.6	152
81	Release of mast cell mediators into the jejunum by cold pain stress in humans. <i>Gastroenterology</i> , 1998, 114, 640-648.	0.6	223
82	Immunological Regulation of Intestinal Epithelial Transport. <i>Digestion</i> , 1998, 59, 404-408.	1.2	9
83	Efficacy of Intravenous Cyclosporine for Steroid Refractory Attacks of Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 285-289.	1.1	53
84	Intravenous Cyclosporine for Steroid-Refractory Attacks of Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 207-210.	1.1	43